Clinical Trial Update: Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)

View source ↗

Summary

A completed post-marketing safety study of Prevenar (pneumococcal conjugate vaccine, 7-valent) with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Prevenar (pneumococcal conjugate vaccine)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Vaccines, Pneumococcal Conjugate Vaccine | Status: COMPLETED | Results posted: 2010-11-16